BioCentury | Apr 17, 2014
Targets & Mechanisms

Unfolding triple-negative breast cancer

A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers-overactivation of the transcription factor X-box binding protein 1 -that could open the door to new therapies for this notoriously...
BioCentury | Dec 6, 2010
Company News

Hard to Treat Diseases, Hb Products Inc. deal

...is in discussions to merge with Hb Products. Hb Products is developing blood transfusion products. Hard to Treat Diseases'...
...Varicella infection is approved in Guatemala. Further terms were not disclosed (see BioCentury, Nov. 22). Hard to Treat Diseases Inc....
BioCentury | Nov 22, 2010
Company News

Hard to Treat Diseases deal

...developing blood transfusion products. The company's MEVAC-Vari vaccine against Varicella infection is approved in Guatemala. Hard to Treat Diseases Inc....
BioCentury | Aug 9, 2010
Company News

Hard to Treat Diseases deal

...Hard to Treat Diseases Inc. (Pink:HTDS), Clearwater, Fla. Business: Neurology, Dermatology Hard to Treat Diseases said it will sell...
BioCentury | Mar 22, 2010
Clinical News

MEVAC-Vari vaccine regulatory update

...its MEVAC-Vari vaccine against Varicella infection. This is the vaccine's first approval in South America. Hard to Treat Diseases Inc....
BioCentury | Jan 25, 2010
Company News

Hard to Treat Diseases deal

...vaccine under a June deal with Walvax Biotech Co. Ltd. (China). At Sept. 30, 2009, Hard to Treat Diseases...
...quarter the company reported a three-month net profit of $33,046 (see BioCentury, Nov. 9, 2009). Hard to Treat Diseases Inc....
BioCentury | Nov 23, 2009
Clinical News

MMR Vaccine regulatory update

...will now consider final approval of the product, which consists of three live attenuated viruses. Hard to Treat Diseases Inc....
BioCentury | Nov 9, 2009
Company News

Hard to Treat Diseases deal

...B vaccine under a June deal with Walvax Biotech Co. Ltd. (China). At June 30, Hard to Treat Diseases...
...had $228,741 in cash and a three-month net profit of $33,046 (see BioCentury, June 22). Hard to Treat Diseases Inc....
BioCentury | Aug 3, 2009
Clinical News

Hard to Treat Diseases preclinical data

...ribavirin attenuated autoimmune encephalomyelitis by limiting cytokine-mediated immuno-inflammatory events that can lead to CNS destruction. Hard to Treat Diseases Inc....
BioCentury | Jun 22, 2009
Company News

Hard to Treat Diseases, Walvax Biotech Co. Ltd. sales and marketing update

...international marketing agreement to market Walvax's Haemophilus influenza type B ( Hib ) conjugate vaccine. Hard to Treat Diseases...
...and will begin the registration process in Chile, India, Indonesia, Egypt and Russia this month. Hard to Treat Diseases Inc....
Items per page:
1 - 10 of 11
BioCentury | Apr 17, 2014
Targets & Mechanisms

Unfolding triple-negative breast cancer

A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers-overactivation of the transcription factor X-box binding protein 1 -that could open the door to new therapies for this notoriously...
BioCentury | Dec 6, 2010
Company News

Hard to Treat Diseases, Hb Products Inc. deal

...is in discussions to merge with Hb Products. Hb Products is developing blood transfusion products. Hard to Treat Diseases'...
...Varicella infection is approved in Guatemala. Further terms were not disclosed (see BioCentury, Nov. 22). Hard to Treat Diseases Inc....
BioCentury | Nov 22, 2010
Company News

Hard to Treat Diseases deal

...developing blood transfusion products. The company's MEVAC-Vari vaccine against Varicella infection is approved in Guatemala. Hard to Treat Diseases Inc....
BioCentury | Aug 9, 2010
Company News

Hard to Treat Diseases deal

...Hard to Treat Diseases Inc. (Pink:HTDS), Clearwater, Fla. Business: Neurology, Dermatology Hard to Treat Diseases said it will sell...
BioCentury | Mar 22, 2010
Clinical News

MEVAC-Vari vaccine regulatory update

...its MEVAC-Vari vaccine against Varicella infection. This is the vaccine's first approval in South America. Hard to Treat Diseases Inc....
BioCentury | Jan 25, 2010
Company News

Hard to Treat Diseases deal

...vaccine under a June deal with Walvax Biotech Co. Ltd. (China). At Sept. 30, 2009, Hard to Treat Diseases...
...quarter the company reported a three-month net profit of $33,046 (see BioCentury, Nov. 9, 2009). Hard to Treat Diseases Inc....
BioCentury | Nov 23, 2009
Clinical News

MMR Vaccine regulatory update

...will now consider final approval of the product, which consists of three live attenuated viruses. Hard to Treat Diseases Inc....
BioCentury | Nov 9, 2009
Company News

Hard to Treat Diseases deal

...B vaccine under a June deal with Walvax Biotech Co. Ltd. (China). At June 30, Hard to Treat Diseases...
...had $228,741 in cash and a three-month net profit of $33,046 (see BioCentury, June 22). Hard to Treat Diseases Inc....
BioCentury | Aug 3, 2009
Clinical News

Hard to Treat Diseases preclinical data

...ribavirin attenuated autoimmune encephalomyelitis by limiting cytokine-mediated immuno-inflammatory events that can lead to CNS destruction. Hard to Treat Diseases Inc....
BioCentury | Jun 22, 2009
Company News

Hard to Treat Diseases, Walvax Biotech Co. Ltd. sales and marketing update

...international marketing agreement to market Walvax's Haemophilus influenza type B ( Hib ) conjugate vaccine. Hard to Treat Diseases...
...and will begin the registration process in Chile, India, Indonesia, Egypt and Russia this month. Hard to Treat Diseases Inc....
Items per page:
1 - 10 of 11